Latest news with #OnoPharmaceuticalCo.
Time Business News
3 days ago
- Business
- Time Business News
New Advances in IAHA Injections for Orthopedic Care
Orthopedic intra-articular hyaluronic acid (IAHA) injection is a treatment where a natural substance found in hyaluronic acid-format fluid is injected into a joint, most commonly to relieve pain, pain, pain and improve mobility in patients with chronic osteoarthritis. The future of orthopedic intra-articular hyaluronic acid (IAHA) injection market looks promising the future, cases of increasing osteoarthritis, the patient's priority for non-surreal treatment, and is inspired by innovations in long-lasting ha formulations. Extending access to emerging markets such as outpatient settings, favorable regulatory support, and Asia-Pacific will further boost demand for increase in demand. Advances such as combination therapy and better distribution methods are also expected to increase the results of treatment and make market access wider. Key Growth Drivers and Opportunities Growing Demand for Minimally Invasive Treatments: Orthopedic intra-articular hyaluronic acid (IAHA) injection market growth primarily due to the rise in the demand for minimally invasive treatments. The main factor is that individuals are more and more turning to fast, safe, and efficient options that do not interfere with their lifestyle. These patients,' electromechanical effector haptic display (EEHD), 'also benefit from a significantly lower recovery time, a crucial aspect when outpatient surgery is concerned. This is why patients and doctors are attracted to this method of treating because it is not only a one-time, surgical method but also a follow-up procedure in most cases by healthcare professionals. Challenges The hyaluronic acid injection field of orthopedics (HA) intra-articular is a limited market. Firstly, in the situation of inconsistent clinical outcomes, not all patients are able to get significant pain relief or improvement in mobility. This is about patients facing the clinical side effects from drugs given by a doctor. Apart from that, the high cost of treatment and the restriction of the purchasing power or the non-reimbursable insurance process will lead to the restraining of the use of the treatment of the patients. The issue of the temporary relief of symptoms will often encourage medication over longer periods, but the need for repetitive injections can serve as a deterrent. Innovation and Expansion JOYCLU, A Monthly Intra-Articular Injection for Osteoarthritis Relief, is introduced by Ono and Seikagaku In May 2021, the joint function improvement drug JOYCLU 30mg Intra-articular Injection (generic name: diclofenac etalhyaluronate sodium; 'JOYCLU') was introduced by Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation. Seikagaku was granted manufacturing and marketing approval in Japan for this product. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks. Hyaluronic acid and the anti-inflammatory medication diclofenac are chemically bound in the JOYCLU formulation by Seikagaku's in-house technology. It is intended to hydrolyze diclofenac in the joint and release it. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks. Inventive Sparks, Expanding Markets Multiple key players currently conduct business in the orthopedic intra-articular hyaluronic acid (IAHA) injection market, for instance, Anika Therapeutics, Inc., Zimmer Biomet, Ferring, LG Chem, Bioventus LLC, and others. By introducing new products, getting involved in the market, teaming up thereby forming partnerships, and through patient education and reimbursement means which also enhance patient access, IAHA-based injectable companies are in the process of their growth. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Business Wire
24-04-2025
- Business
- Business Wire
Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; 'ONO') announced that it will present positive results from the Phase 2 PROSPECT study of tirabrutinib (ONO-4059) for the treatment of relapsed or refractory primary central nervous system lymphoma during an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30 to June 3, 2025, in Chicago, Illinois. The company will also present data on ONO-4578, an investigational EP4 antagonist, for the treatment of locally advanced resectable rectal cancer, during a poster presentation. "We are fully committed to developing innovative drugs for cancer patients. This announcement is an important step forward in demonstrating that we can potentially provide new value to patients,' said Tatsuya Okamoto, Corporate Officer / Executive Director, Clinical Development at ONO. 'We aim to offer new treatment options in cancer care globally and contribute to improving patients' quality of life." Details for both studies and data to be presented are as follows: Tirabrutinib (ONO-4059) Abstract Title: Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study. Abstract Submission ID: 487376 Session Type and Title: Rapid Oral Abstract – Central Nervous System Tumors Session Date and Time: May 31, 2025, 3:00-4:30 PM CDT Presenter: Lakshmi Nayak, MD, Dana-Farber Cancer Institute ONO-4578 Abstract Title: Neoadjuvant ONO-4578, an EP4 antagonist, in combination with nivolumab after chemoradiation therapy in locally advanced resectable rectal cancer. Session Type and Title: Poster Session Gastrointestinal Cancer – Colorectal and Anal Abstract Number for Publication: 3588 Poster Board: 257 Session Date and Time: May 31, 2025, 9:00 AM-12:00 PM CDT Presenter: Yusuke Takahashi, Lower Gastrointestinal Surgery, National Hospital Organization Osaka National Hospital About Ono Pharmaceutical Co., Ltd Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of 'Dedicated to the Fight against Disease and Pain,' Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at
